SBC Medical Group Holdings (SBC) Q4 2024 earnings summary

Executive summary

• FY2024 revenue increased 6% year-over-year to $205 million, with net income up 18% to $47 million and EPS up 14% to $0.48, driven by franchise clinic expansion and strategic pricing.

• Customer count rose 15% to 6.03 million, with a 71% repeat rate and 43 new clinics opened, totaling 251 clinics.

• EBITDA reached $89 million (up 8% YoY), with a stable 43% margin; excluding one-time items, EBITDA rose 32%.

• Strategic price revisions and clinic expansion, especially in aesthetic dermatology, drove growth.

• NASDAQ listing in September incurred one-time stock-based compensation and impairment losses.

Financial highlights

• Gross profit for FY2024 was $156 million (up 14% YoY); operating income was $70 million, nearly flat YoY.

• Basic EPS was $0.48, up 14% year-over-year; Q4 EPS was $0.06, down 58% YoY.

• Cash and cash equivalents rose to $125 million at year-end 2024, with a current ratio of 301%.

• Net cash from operations was $20.6 million, down from $50.7 million in 2023.

• Q4 2024 saw a 29% revenue decline and a 54% drop in net income year-over-year.

Outlook and guidance

• Strategic price increases in medical hair removal (approx. 20%) and franchise fee revisions planned for 2025.

• New tiered franchise fee system launches April 2025; if applied in 2024, revenues would have been ~10% lower.

• Expansion targeted in Asia (Vietnam, Singapore, Thailand, Indonesia, India) and the U.S., with a mix of direct and franchise models.

• Plans to organically increase net clinics by 20 in 2025, with additional growth possible via M&A.

• Focus on increasing market penetration in Japan from 12% to at least 20%.